ABS0554 FEATURES OF ANTI-FIBRILLARIN POSITIVE SYSTEMIC SCLEROSIS PATIENTS AND ETHNIC DIFFERENCES: A EUROPEAN MULTICENTRIC COHORT
R. D’Alessandro(Hôpital Cochin), Y. Allanore(Hôpital Cochin), I. Castellví(Hospital de Sant Pau), Stefano Rodolfi(Royal Free London NHS Foundation Trust), D. Launay(Université de Lille), F. Del Galdo(NIHR Leeds Musculoskeletal Biomedical Research Unit), P. Airò(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), J. Avouac(Hôpital Cochin), S. Bellando‐Randone(Azienda Ospedaliero-Universitaria Careggi), C. Campochiaro(Vita-Salute San Raffaele University), Veronica Codullo(Université de Strasbourg), L. Raffray(University of Reunion Island), Emmanuel Chatelus(Laboratoire National de Référence), A Collet(Université de Lille), CP Denton(The Royal Free Hospital), P. Cacoub(Sorbonne Université), Alain Lescoat(Inserm), Elisabetta Zanatta(University of Padua), L. Bébéar(Université de Bordeaux), A. Lejoncour(Sorbonne Université), C. Sieiro Santos(Utrecht University), A. Calot(Hôpital Cochin), Gonçalo Boleto(University of Lisbon)
Cited by 0
Related Papers
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207